Cellyan Biotechnology (HKPD) Current Leases (2024 - 2025)

Cellyan Biotechnology's (HKPD) quarterly Current Leases came in at $452940.0 in Q3 2025, down 8.14% on a QoQ basis from $493103.0 in Q1 2025.

Cellyan Biotechnology (HKPD) Current Leases (2024 - 2025) Analysis & Trends

Cellyan Biotechnology (HKPD) has 2 years of Current Leases data on file, last reported at $452940.0 in Q3 2025.

  • On a quarterly basis, Current Leases changed N/A year-over-year to $452940.0 in Q3 2025; TTM through Sep 2025 was $452940.0, a N/A change from a year earlier, with the FY2025 full-year figure at $493103.0, down 22.29% from the prior year.
  • Current Leases for Q3 2025 stood at $452940.0, down from $493103.0 in the prior quarter.
  • Over the last five years, Current Leases for HKPD reached as high as $634504.0 in Q1 2024 and fell as low as $452940.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Current Leases (Qtr)
1 Mckesson 105.15 Bn 101.18 Bn 4.04 Bn 287.00 Mn
2 Cencora 60.58 Bn 58.40 Bn 3.59 Bn -
3 Cardinal Health 53.81 Bn 49.87 Bn 2.50 Bn -
4 Henry Schein 9.71 Bn 9.57 Bn 1.07 Bn 78.00 Mn
5 Akso Health 3.28 Bn 3.28 Bn - 22,567.00
6 111 651.73 Mn 572.63 Mn 23.58 Mn 2.70 Mn
7 Accendra Health 248.02 Mn -88.86 Mn 278.03 Mn -
8 Edap Tms 230.14 Mn 215.14 Mn 8.15 Mn 918,000.00
9 VitaNova Life Sciences 11.51 Mn 11.01 Mn 316,343.00 -
10 Cellyan Biotechnology 4.19 Mn 3.44 Mn - 452,940.00

Historic Data

Download Data
DateValue
Sep 30, 2025 452,940.00
Mar 31, 2025 493,103.00
Mar 31, 2024 634,504.00